342 related articles for article (PubMed ID: 28196734)
1. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
[TBL] [Abstract][Full Text] [Related]
2. Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.
Harris SL; Donald RG; Hawkins JC; Tan C; O'Neill R; McNeil LK; Perez JL; Anderson AS; Jansen KU; Jones TR
Pediatr Infect Dis J; 2017 Feb; 36(2):216-223. PubMed ID: 27846061
[TBL] [Abstract][Full Text] [Related]
3. Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.
McNeil LK; Donald RGK; Gribenko A; French R; Lambert N; Harris SL; Jones TR; Li S; Zlotnick G; Vogel U; Claus H; Abad R; Vazquez JA; Borrow R; Findlow J; Taha MK; Deghmane AE; Caugant DA; Kriz P; Musilek M; Wang X; Vuong J; Mayer LW; Pride MW; Jansen KU; Anderson AS
mBio; 2018 Mar; 9(2):. PubMed ID: 29535195
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.
Senders S; Bhuyan P; Jiang Q; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Ginis J; Perez JL
Pediatr Infect Dis J; 2016 May; 35(5):548-54. PubMed ID: 26835974
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
[TBL] [Abstract][Full Text] [Related]
6. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
Vesikari T; Østergaard L; Diez-Domingo J; Wysocki J; Flodmark CE; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Crowther G; Perez JL
J Pediatric Infect Dis Soc; 2016 Jun; 5(2):152-60. PubMed ID: 26407272
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.
Marshall HS; Richmond PC; Nissen MD; Wouters A; Baber J; Jiang Q; Anderson AS; Jones TR; Harris SL; Jansen KU; Perez JL
Vaccine; 2013 Mar; 31(12):1569-75. PubMed ID: 23352429
[TBL] [Abstract][Full Text] [Related]
8. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
[TBL] [Abstract][Full Text] [Related]
9. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
Jiang HQ; Hoiseth SK; Harris SL; McNeil LK; Zhu D; Tan C; Scott AA; Alexander K; Mason K; Miller L; DaSilva I; Mack M; Zhao XJ; Pride MW; Andrew L; Murphy E; Hagen M; French R; Arora A; Jones TR; Jansen KU; Zlotnick GW; Anderson AS
Vaccine; 2010 Aug; 28(37):6086-93. PubMed ID: 20619376
[TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.
Nissen MD; Marshall HS; Richmond PC; Jiang Q; Harris SL; Jones TR; Jansen KU; Perez JL
Pediatr Infect Dis J; 2013 Apr; 32(4):364-71. PubMed ID: 23114369
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
Gandhi A; Balmer P; York LJ
Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
Rossi R; Beernink PT; Giuntini S; Granoff DM
Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
[TBL] [Abstract][Full Text] [Related]
13. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
[TBL] [Abstract][Full Text] [Related]
14. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
Marshall HS; Richmond PC; Nissen MD; Jiang Q; Anderson AS; Jansen KU; Reynolds G; Ziegler JB; Harris SL; Jones TR; Perez JL
Pediatr Infect Dis J; 2012 Oct; 31(10):1061-8. PubMed ID: 22718089
[TBL] [Abstract][Full Text] [Related]
16. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents.
Vesikari T; Wysocki J; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Perez JL
J Pediatric Infect Dis Soc; 2016 Jun; 5(2):180-7. PubMed ID: 26803328
[TBL] [Abstract][Full Text] [Related]
18. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
[TBL] [Abstract][Full Text] [Related]
19. Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years.
Shirley M; Dhillon S
BioDrugs; 2015 Oct; 29(5):353-61. PubMed ID: 26394633
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.
Harris SL; Zhu D; Murphy E; McNeil LK; Wang X; Mayer LW; Harrison LH; Jansen KU; Anderson AS
Hum Vaccin; 2011; 7 Suppl(Suppl):68-74. PubMed ID: 21245657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
